Physician profile
Erin Johnson
NPI 1306079165
$4,629.67
in general payments reported to CMS, 2019-2025
42 companies · $811 in 2025
The $811 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $411 · 2021: $521 · 2022: $451 · 2023: $734 · 2024: $1,309 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,350.96 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astrazeneca Pharmaceuticals LP | $753.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $362.03 | 2023-2025 | |
| Lilly USA, LLC | $333.28 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $317.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.52 | 2019-2024 | Synjardy, Jardiance |
| Novo Nordisk INC | $161.80 | 2020-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.64 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $92.07 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $86.74 | 2019-2025 | Gattex, Trintellix |
| Vanda Pharmaceuticals INC. | $77.77 | 2024-2025 | Fanapt |
| Astellas Pharma US INC | $72.21 | 2023-2024 | Veozah, Myrbetriq |
| Alexion Pharmaceuticals, INC. | $65.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $41.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $37.50 | 2022-2025 | Auvelity |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.